OUR PIPELINE

We are Pioneering Innovation to Further Improve Sight

“Improving vision remains the greatest unmet need in retinal diseases. Our team is dedicated to achieving the unprecedented – we are developing a novel, first-in-class anti-VEGF-C/D ‘trap’ inhibitor in combination with anti-VEGF-A therapies to transform the current standard of care.”

Fred Gerard, PharmD
Chief Executive Officer

Explore Our Pipeline

Sozinibercept is the only product in late-stage clinical development for wet AMD with the potential to be the first therapy in 20 years to deliver superior visual gains for patients suffering from this debilitating disease.

PHASE OF DEVELOPMENT

PROGRAM

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

ANTICIPATED MILESTONES

SOZINIBERCEPT
For use in combination with anti-VEGF-A therapies

TOPLINE DATA:
COAST (IN EARLY 2Q CY2025)
SHORE (IN MID-CY2025)

Diabetic Macular Edema (DME)

SOZINIBERCEPT
For use in combination with anti-VEGF-A therapies

PHASE 3 READY

Co-formulation (Sozinibercept + VEGF-A Inhibitor)

SOZINIBERCEPT
Co-formulation with VEGF-A Inhibitor

FEASIBILITY
UNDERWAY

Sozinibercept was granted ‘Fast Track’ designation by the US Food and Drug Administration in 2021. This recognition highlights sozinibercept’s novel mechanism of action and its potential to deliver superior vision gains to patients with wet AMD.

Topline results for COAST are expected in early Q2/2025 and for ShORe in mid 2025.
Sozinibercept is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST and ShORe) designed to assess the safety and efficacy of sozinibercept combination therapy versus standard-of-care anti-VEGF-A therapies alone for the treatment of wet AMD.

We are also working to advance our clinical development program of sozinibercept in diabetic macular edema (DME) as well as investigating the feasibility of a co-formulation of sozinibercept with a VEGF-A inhibitor.

Sozinibercept was granted ‘Fast Track’ designation by the US Food and Drug Administration in 2021. This recognition highlights sozinibercept’s novel mechanism of action and its potential to deliver superior vision gains to patients with wet AMD.

Topline results for COAST are expected in early Q2/2025 and for ShORe in mid 2025.
Sozinibercept is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST and ShORe) designed to assess the safety and efficacy of sozinibercept combination therapy

versus standard-of-care anti-VEGF-A therapies alone for the treatment of wet AMD.

We are also working to advance our clinical development program of sozinibercept in diabetic macular edema (DME) as well as investigating the feasibility of a co-formulation of sozinibercept with a VEGF-A inhibitor.

Learn more about about our clinical trials in WET AMD and DME

How we are targeting superior visual gains

Sozinibercept in combination with anti-VEGF-A has the potential to elevate the standard of care in wet AMD.

A ‘trap’ comprising the extracellular domains 1-3 of VEGFR-3 and the FC fragment of 1gG1

Potent inhibitor of VEGF-C and VEGF-D

10 kDa

Comparable ocular biodistribution and similar ocilar pharmacokinetics to aflibercent 2mg

Sozinibercept Fully Human Molecule

Sozinibercept

Is a novel, first-in-class VEGF-C/D ‘trap’ fusion protein.
Is the only late-stage drug in development targeting superior visual outcomes.
Has the potential to raise the standard-of-care benchmark in visual outcomes.
Has characteristics to match extended dosing regimens and well-tolerated safety profiles of standard-of-care therapies.

Learn more about our bold approach of improving vision